(Q54352754)

28 May 2018

title

Phase II, randomized, biomarker identification trial (MARK) for erlotinib in patients with advanced pancreatic carcinoma. (English)

1 reference

28 May 2018

main subject

biomarker

0 references

phase II clinical trial

0 references

author name string

D Propper

1

1 reference

28 May 2018

I Davidenko

2

1 reference

28 May 2018

J Bridgewater

3

1 reference

28 May 2018

L Kupcinskas

4

1 reference

28 May 2018

A Fittipaldo

5

1 reference

28 May 2018

C Hillenbach

6

1 reference

28 May 2018

B Klughammer

7

1 reference

28 May 2018

M Ducreux

8

1 reference

28 May 2018

publication date

14 May 2014

1 reference

28 May 2018

published in

Annals of Oncology

1 reference

28 May 2018

volume

25

1 reference

28 May 2018

issue

7

1 reference

28 May 2018

page(s)

1384-1390

1 reference

28 May 2018

The molecular and cellular heterogeneity of pancreatic ductal adenocarcinoma

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU176

New therapeutic directions for advanced pancreatic cancer: targeting the epidermal growth factor and vascular endothelial growth factor pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU176

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU176

Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer: National Cancer Institute of Canada Clinical Trials Group Study PA.3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU176

Sequential Treatment Assignment with Balancing for Prognostic Factors in the Controlled Clinical Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU176

Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU176

Screening for epidermal growth factor receptor mutations in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU176

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU176

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU176

EGFR ligands exhibit functional differences in models of paracrine and autocrine signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU176

Altered EGFR localization and degradation in human breast cancer cells with an amphiregulin/EGFR autocrine loop.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU176

Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU176

Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival of pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU176

Tissue biomarkers for prognosis in pancreatic ductal adenocarcinoma: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU176

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDU176

1 reference

28 May 2018

1 reference

28 May 2018